IP Library Granted Patent US 8,865,731
Granted Patent B2
US 8,865,731 · App. 12/994,923 · Granted Oct 21, 2014

Inhibitor of analgesic tolerance

Inventors: Jun Ouchi (Shizuoka, JP); Shunji Kunori (Shizuoka, JP); Yozo Kojima (Shizuoka, JP); Katsumi Shinoda (Tokyo, JP); Katsutoshi Sasaki (Shizuoka, JP); Shiro Shirakura (Shizuoka, JP)
Assignee: Kyowa Hakko Kirin Co., Ltd.
C07D417/14A61K31/522A61K31/4439C07D473/34C07D473/06C07D487/14C07D417/04A61K31/506A61K45/06A61K31/343C07D487/04A61K31/52A61K31/427A61K31/519A61K31/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,731
App. No.
12/994,923
Granted
Oct 21, 2014
Kind
B2
Abstract

Provided are: an agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), which comprises a compound having adenosine A 2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof as an active ingredient; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance or constipation; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance; and the like.

Claims (14)

1. A method for suppressing an undesirable effect of an opioid, which comprises administering an effective amount of a compound represented by at least one of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof:

in which R 1 represents a hydrogen atom or methyl; R 2 and R 3 independently represent methyl, ethyl, propyl, butyl or isopropyl; R 4 , R 5 and R 6 independently represent a hydrogen atom, methyl, ethyl, methoxy, ethoxy, a fluorine atom, a chlorine atom or a bromine atom; R 7 represents methyl, ethyl, propyl, butyl or 3-methylbutyl, each of which is optionally substituted with hydroxy; R 8 represents phenyl, pyridyl, pyrimidinyl or 5,6-dihydro-2H-pyridylmethyl, each of which is optionally substituted with 1 to 3 substituents selected from the group consisting of a chlorine atom, methyl, ethyl, methoxy and ethoxy; R 9 represents pyridyl or tetrahydropyranyl; R 10 and R 11 independently represent a hydrogen atom, a fluorine atom or 2-methoxyethoxy; and R 12 represents methyl, ethyl, propyl or butyl, wherein

said undesirable effect is analgesic tolerance.

2. The method according to claim 1 , wherein the opioid is selected from the group consisting of anileridine, opium, ampromide, allylprodine, alphaprodine, alfentanil, isomethadone, ethylmethylthiambutene, ethylmorphine, ethoheptazine, etonitazene, eptazocine, endorphin, enkephalin, oxycodone, oxymorphone, clonitazene, ketobemidone, cocaine, codeine, cylmorphan, diamorphone, dioxaphetylbutyrate, didezocine, dinorphine, dihydrocodeine, dihydromorphine, dipipanone, dimethylthiambutene, dimenoxadol, dimepheptanol, sufentanil, tilidine, dextromoramide, desomorphine, tramadol, narceine, nalorphine, nalbuphene, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, papaveretum, hydrocodone, hydroxypethidine, hydromorphone, piminodine, piritramide, fentanyl, phenazocine, phenadoxone, phenoperidine, phenomorphan, butorphanol, buprenorphine, properidine, propoxyphene, propheptazine, promedol, heroin, bezitramide, berzylmorphine, pentazocine, myrophine, methadone, metazocine, metopon, meptazinol, meperidine, morphine, levallorphan, levophenalofentanil, levorphanol, and remifentanil.

3. The method according to claim 1 , wherein the opioid is morphine.

4. The method according to claim 1 , wherein the compound is represented by at least one of formula (IA), (IB), (IC), (ID), (IIA), (IIIA), (IIIB), (IIIC), (IVA), (V), (VIA), (VII) or (VIII), or a pharmaceutically acceptable salt thereof:

5. The method according to claim 1 , wherein the compound is represented by at least one of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof:

6. The method according to claim 1 , wherein the compound is represented by formula (IIIC), or a pharmaceutically acceptable salt thereof:

7. The method according to claim 4 , wherein the opioid is selected from the group consisting of anileridine, opium, ampromide, allylprodine, alphaprodine, alfentanil, isomethadone, ethylmethylthiambutene, ethylmorphine, ethoheptazine, etonitazene, eptazocine, endorphin, enkephalin, oxycodone, oxymorphone, clonitazene, ketobemidone, cocaine, codeine, cylmorphan, diamorphone, dioxaphetylbutyrate, didezocine, dinorphine, dihydrocodeine, dihydromorphine, dipipanone, dimethylthiambutene, dimenoxadol, dimepheptanol, sufentanil, tilidine, dextromoramide, desomorphine, tramadol, narceine, nalorphine, nalbuphene, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, papaveretum, hydrocodone, hydroxypethidine, hydromorphone, piminodine, piritramide, fentanyl, phenazocine, phenadoxone, phenoperidine, phenomorphan, butorphanol, buprenorphine, properidine, propoxyphene, propheptazine, promedol, heroin, bezitramide, berzylmorphine, pentazocine, myrophine, methadone, metazocine, metopon, meptazinol, meperidine, morphine, levallorphan, levophenalofentanil, levorphanol, and remifentanil.

8. The method according to claim 4 , wherein the opioid is morphine.

9. The method according to claim 5 , wherein the opioid is selected from the group consisting of anileridine, opium, ampromide, allylprodine, alphaprodine, alfentanil, isomethadone, ethylmethylthiambutene, ethylmorphine, ethoheptazine, etonitazene, eptazocine, endorphin, enkephalin, oxycodone, oxymorphone, clonitazene, ketobemidone, cocaine, codeine, cylmorphan, diamorphone, dioxaphetylbutyrate, didezocine, dinorphine, dihydrocodeine, dihydromorphine, dipipanone, dimethylthiambutene, dimenoxadol, dimepheptanol, sufentanil, tilidine, dextromoramide, desomorphine, tramadol, narceine, nalorphine, nalbuphene, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, papaveretum, hydrocodone, hydroxypethidine, hydromorphone, piminodine, piritramide, fentanyl, phenazocine, phenadoxone, phenoperidine, phenomorphan, butorphanol, buprenorphine, properidine, propoxyphene, propheptazine, promedol, heroin, bezitramide, berzylmorphine, pentazocine, myrophine, methadone, metazocine, metopon, meptazinol, meperidine, morphine, levallorphan, levophenalofentanil, levorphanol, and remifentanil.

10. The method according to claim 5 , wherein the opioid is morphine.

11. The method according to claim 6 , wherein the opioid is selected from the group consisting of anileridine, opium, ampromide, allylprodine, alphaprodine, alfentanil, isomethadone, ethylmethylthiambutene, ethylmorphine, ethoheptazine, etonitazene, eptazocine, endorphin, enkephalin, oxycodone, oxymorphone, clonitazene, ketobemidone, cocaine, codeine, cylmorphan, diamorphone, dioxaphetylbutyrate, didezocine, dinorphine, dihydrocodeine, dihydromorphine, dipipanone, dimethylthiambutene, dimenoxadol, dimepheptanol, sufentanil, tilidine, dextromoramide, desomorphine, tramadol, narceine, nalorphine, nalbuphene, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, papaveretum, hydrocodone, hydroxypethidine, hydromorphone, piminodine, piritramide, fentanyl, phenazocine, phenadoxone, phenoperidine, phenomorphan, butorphanol, buprenorphine, properidine, propoxyphene, propheptazine, promedol, heroin, bezitramide, berzylmorphine, pentazocine, myrophine, methadone, metazocine, metopon, meptazinol, meperidine, morphine, levallorphan, levophenalofentanil, levorphanol, and remifentanil.

12. The method according to claim 6 , wherein the opioid is morphine.

Assignments (2)
CHANGE OF NAME Recorded Dec 16, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051306/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2011
From: OUCHI, JUN; KUNORI, SHUNJI; KOJIMA, YOZO; SHINODA, KATSUMI; SASAKI, KATSUTOSHI; SHIRAKURA, SHIRO
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 025571/0803 →
Priority Claims (2)
JP 2008-141178 · May 29, 2008 · national
JP 2008-302783 · Nov 27, 2008 · national
Continuity (1)
Related Publication 20110105465A1 · May 5, 2011